Pharma giant Pfizer selected its new executive leadership team that will report to incoming CEO Albert Bourla, PhD, effective Jan. 1.
The leadership team announcement comes just one week after the drugmaker's current CEO and Chairman Ian Read said he would step down from his roles Jan. 1 after eight years on the job.
"We are at a pivotal moment in Pfizer's history, with Ian Read having positioned the company with a strong portfolio of marketed products, a deep pipeline and the clear potential to accelerate our revenue growth," said Dr. Bourla. "Given this opportunity to realize this accelerated growth potential, we are creating an executive team that has a proven record of success, an unwavering commitment to the patients we serve, and a clear value creation initiative. I look forward to working with these outstanding leaders to achieve the full potential of our pipeline and deliver our next stage of growth."
Here is Pfizer's executive leadership team:
- Frank D'Amelio — CFO, executive vice president and head of Pfizer Global Supply
- Mikael Dolsten, MD, PhD — CMO, global president of worldwide research and development
- Michael Goettler — global president of established medicines
- Angela Hwang — group president of innovative medicines
- Rady Johnson — chief compliance officer and executive vice president
- Doug Lankler — general counsel and executive vice president
- Freda Lewis-Hall, MD — chief patient officer and executive vice president
- Rod MacKenzie, PhD — chief development officer and executive vice president
- Dawn Rogers — chief human resources officer and executive vice president
- Sally Susman — chief corporate affairs officer and executive vice president
- John Young — chief business officer, head of strategy and commercial operations
- Lidia Fonseca — chief digital officer